Argenx submits biologics license application to u.s. food and drug administration for subcutaneous efgartigimod for treatment of generalized myasthenia gravis

Submission package based on positive data from the phase 3 adapt-sc trial demonstrating noninferiority of subcutaneous (sc) efgartigimod compared to intravenously administered vyvgart® (efgartigimod alfa-fcab) based on total immunoglobulin g (igg) reduction at day 29

ARGX Ratings Summary

ARGX Quant Ranking